Project Information AT A GLANCE
Project Title: DENDRI’MS: An immuno-modulatory phosphorus-based dendrimer for the treatment of Multiple Sclerosis
Project Objective: Validate dendrimer ABP as an innovative drug- candidate in MS with Proof of Concept in mouse and non-human primate (NHP) EAE models; Depict the immunological properties of dendrimer ABP in these models, including its Blood-Brain Barrier crossing property; Address immuno-safety concerns regarding dendrimer ABP in a NHP model.
“We are beginning to plan the transition from mouse to man- like primate models”
Initially, experiments will rely on mouse-based models, before focusing on closer analogues. Building on a 2006 study of ABP
dendrimers, the project unites a team of diverse experts. “Experiences are shared. We’ve been using this strategy with success for the past decade,” relates the Project Co-ordinator, who describes their working relationship as a “synergy”. Himself an authority in biochemistry and immunology (particularly innate immunity) at the Physiopathology Center of Toulouse-Purpan, two of Poupot’s long term collaborators are Anne-Marie Caminade and Cédric-Olivier Turrin of the Laboratoire de Chimie de Coordination – also at the forefront of investigations into dendrimer based nano-medicines. Professor Roland Liblau, also from the Physiopathology Center of Toulouse- Purpan, offers neurological and immunological insights on MS, whilst a fifth senior member of the group, Hugues Contamin, PhD, CEO of Cynbiose, a biotech company, is an internationally renowned specialist in primatology. “We are beginning to plan the
transition from mouse to man-like primate models” details the Professor. “This is a very tricky area due to their differing biology (and from an ethical standpoint), and will occupy us over the next few months”. Although the study
92
does not presently contain human trials, the team intends to compile sufficient data – and obtain additional funding – to enter phase 1 clinical trials, which could validate the positive indications of initial tests. Before this technology is embraced by the healthcare mainstream, however, long- standing statutes will need to be rewritten. Dendrimers, relates the Project
Co-ordinator, are “larger molecules”, compared with
other chemicals
drugs. As such, they violate the Lipinski’s “rule of 5” covering drug candidates, exceeding size and weight specifications. For some observers in the medical industry, the suggestion that such treatments could prove effective nears heresy. Poupot, however, counters that his research offers a strong rebuttal to orthodoxy. “Our conclusion after conducting several dendrimer- based studies is that, although we accept the necessity for rules governing medicinal molecules, one day or another a drug will appear which does not respect the ‘five rules’” he says. If this latest strand of
research attains ★ its laudable
goals, ABP dendrimers may be the one to rewrite them.
Project Duration and Timing: DENDRI’MS was launched in January 2012 and will run for 36 months
Project Funding: French National Research Agency (ANR, Agence Nationale de la Recherche), program “Partnership Research and Biomedical Innovation”
Project Partners: • Centre of Physiopathology of Toulouse- Purpan (CPTP, Pr. Rémy POUPOT and Pr. Roland LIBLAU)
• Laboratory of Coordination Chemistry (LCC, Dr. Anne-Marie CAMINDE and Dr. Cédric- Olivier TURRIN)
• CYNBIOSE (CEO: Dr. Hugues CONTAMIN)
Other research and development partners: • Laboratory of Applied Mathematics and Physics (LaMFI, Dr. Giovanni PAVAN)
• Innovative Concept in Drug Development (ICDD, CEO: Dr. Nathalie COMPAGNONE)
• INSERM Transfert Initiative (CEO: Dr. Mounia CHAOUI)
Main Contact:
Pr. Rémy POUPOT Dr. Rémy POUPOT received his PhD in Biochemistry from the University Paul Sabatier of Toulouse. He is currently full professor in Biochemistry in the same University. His research interests include immunology (in particular innate immunity), molecular mechanisms underlying immuno- modulation triggered by natural and chemical stimuli.
Contact: Tel: +33 (0)562 748 661 Email:
remy.poupot@inserm.fr
Insight Publishers | Projects
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132